Takeda to Acquire Late-Stage, Potential Best-in-Class, Oral Allosteric TYK2 Inhibitor NDI-034858 From Nimbus Therapeutics

13.12.2022 - Takeda (TSE:4502/NYSE:TAK) today announced that it will acquire NDI-034858 from Nimbus Therapeutics. NDI-034858 is an oral, selective allosteric tyrosine kinase 2 (TYK2) inhibitor being evaluated for the treatment of multiple autoimmune diseases ...

Related Keywords

Japan ,Boston ,Massachusetts ,United States ,Osaka ,Cambridge ,Cambridgeshire ,United Kingdom ,Catherine Wilson ,Nimbus Therapeutics ,Takeda Yakuhin Kogyo ,Jeb Keiper ,Jun Saito ,Christopher Oreilly ,Research Development At Takeda ,Nimbus Lakshmi Inc ,Exchange Commission ,Cleary Gottlieb Steen Hamilton ,Takeda Pharmaceutical Company Limited ,Program Subsidiary ,Evercore Group ,Andy Plump ,Costa Saroukos ,Antitrust Improvements Act ,Cleary Gottlieb Steen ,Rare Genetics ,Plasma Derived Therapies ,Pharmaceutical Company Limited ,Annual Report ,Nimbus Lakshmi ,Acquire Late Stage ,Potential Best In Class ,Oral Allosteric ,Wharf Road ,Chief Executive Officer ,Common Stock ,Seriesb Common Stock ,Rare Genetic ,Takeda Yakuhin Kogyo Stock ,